uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.

3-D Rendering Red Blood Cells
uniQure and CSL Behring announced positive Phase III data for EtranaDez in hemophilia B • Source: Shutterstock

After a delay in their original filing plans, uniQure N.V. and CSL Limited (CSL Behring) have come back with Phase III data on etranacogene dezaparvovec (EtranaDez) in hemophilia B that should be sufficient to seek US Food and Drug Administration approval for the gene therapy in the first half of 2022, in addition to opening up a significant commercial opportunity.

The companies said on 9 December that the HOPE-B trial met the primary endpoint of non-inferiority in annualized bleeding rate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances KOSH SANDBOX

 
• By 

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Quick Listen: Scrip's Five Must-Know Things

 
• By 

In this week's podcast edition of Five Must-Know Things: Merck & Co. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal’s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.

Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

 

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

More from Advanced Therapies

spo

Akash test for clone

Test article to check the clone issue

Live test

 

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.